Dashboard
My Portfolio
Backtest
New
Portfolios
Investors
Analysts
Community
Calendars
Economic Calendar
Dividend Calendar
Earnings Calendar
Splits Calendar
IPO Calendar
Markets
Stocks
Indices
Forex
Crypto
Commodities
News
Sign Up
Sign In
Your search results will appear here.
Light Mode
Dark Mode
Sign Up
Sign In
Xuanzhu Biopharmaceutical Co., Ltd. (2575)
Market Closed
17 Sep, 08:00 AM
HKEX
All
(2)
DE
(1)
HK
(1)
HKEX
Primary
XFRA
9.
09
HKD
+0.96
+11.8081%
HKD
32.63B
Market Cap
-
P/E Ratio
-
Div Yield
19.12M
Volume
-
Eps
8.13
HKD
Previous Close
Watching
Watch
Add Transaction
Day Range
8.13
11.72
Year Range
8.01
96.9
Want to track
2575
and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free
Overview
Statistics
Historical Data
Xuanzhu Biopharmaceutical Co., Ltd. (2575) Statistics
Valuation metrics
Market Cap
32.63B
Enterprise value
3.7B
Trailing P/E (ttm)
-17.37
Forward P/E
-
PEG ratio
-0.15
Price/Sales (ttm)
36.67
Price/Book (mrq)
2.87
Enterprise Value/Revenue
31.65
Enterprise Value/EBITDA
-19.93
Overview
Shares outstanding
517.95M
Float
142.8M
Shares short
-
% Held by insiders
0.85%
% Held by institutions
0.01%
Average volume (10 days)
4.25M
Average volume (90 days)
1.8M
Price summary
52-Week low
8.01
52-Week high
96.9
Beta
-
50-Day moving average
9.18
200-Day moving average
16
Financials
Fiscal year
Fiscal year ends
31 Dec 2025
Most recent quarter (mrq)
31 Dec 2025
Profitability
Profit margin
-2.01%
Operating margin
-1.82%
Operational effectiveness
Return on assets
-0.13%
Return on equity
-0.16%
Income Statement
Revenue (ttm)
59.93M
Revenue per share (ttm)
0.23
Quarterly revenue growth (yoy)
1.41%
Gross profit (ttm)
29.77M
EBITDA
-238.05M
Net income to common (ttm)
-284.21M
Diluted EPS (ttm)
-0.45
Quarterly earnings growth (yoy)
-
Balance Sheet
Total cash (mrq)
755.09M
Total cash per share (mrq)
1.13
Total debt (mrq)
748.99K
Total Debt/Equity (mrq)
0
Current ratio (mrq)
3.69%
Book value per share (mrq)
2.89
Cash Flow
Cash flow statement
-243.06M
Levered free cash flow (LFCF)
-197.58M